Clinical Trials

Alpine is committed to bringing innovative new drug therapies to patients with serious or life-threatening diseases or conditions.

Active Studies

Povetacicept (ALPN-303)

PHASE 1

A Study of Povetacicept in Adult Healthy Volunteers

The goal of this study was to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of povetacicept.

STUDY NUMBER
NCT05034484

INDICATION(S)
N/A

Ruby 3

PHASE 1b/2a

An Open-Label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases

The goal of this open-label clinical study is to evaluate multiple dose levels of povetacicept (ALPN-303) in adults with autoimmune kidney disease to determine if povetacicept is safe and potentially beneficial in treating these diseases.

Ruby3ClinicalStudy.com

STUDY NUMBER
NCT05732402

INDICATION(S)
Immunoglobulin A (IgA) Nephropathy, Primary Membranous Nephropathy, or Lupus-Related Kidney Disease (Lupus Nephritis)

Ruby 4

PHASE 1b

An Open-label Study of Povetacicept (ALPN-303) in Subjects With Autoimmune Cytopenias

The goal of this clinical study is to evaluate povetacicept (ALPN-303) in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases.

Ruby4ClinicalStudy.com

STUDY NUMBER
NCT05757570

INDICATION(S)
Immune Thrombocytopenia, Idiopathic Thrombocytopenic Purpura, Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease

Related Materials

Learn more about the povetacicept studies from recent presentations at scientific conferences and manuscript publications.

Acazicolcept (ALPN-101)

Synergy logo

PHASE 2

A Randomized, Double-Blind, Placebo-Controlled Study of ALPN-101 in Systemic Lupus Erythematosus

The goal of this multinational, randomized, blinded study is to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of acazicolcept (ALPN-101) in adults with moderate to severe active systemic lupus erythematosus (SLE).

STUDY NUMBER
NCT04835441

INDICATION(S)
Systemic Lupus Erythematosus

Expanded Access

Alpine is committed to bringing innovative new drug therapies to patients with serious or life-threatening diseases or conditions. Participation in a clinical trial is currently the most appropriate way to access our investigational therapies.

In line with the 21st Century Cures Act (Pub.L. 114-255), Alpine may revise this policy at any time.

Additional Resources

Join us in the discovery and development of next-generation immunotherapies.

Current job openingsLearn more about Alpine